

## ASX ANNOUNCEMENT

23 February 2026

### Biome First Half FY26 Results and Highlights


#### Financial Highlights:

- Biome reports record H1 net profit of \$1.18m (1H25: \$0.43m), up 172%
- Record H1 EBITDA of \$1.47m (excluding share-based payments)
  - Eighth consecutive quarter of positive EBITDA in Q2
- Record half-year sales revenue of \$12.40m
  - Up ~40% vs PCP
  - Q2 FY26 revenue of \$6.45m
- Annualised revenue run rate of ~\$25.8m exiting Q2
- Gross margin of 61.1% achieved (1H25: 61.0%)
- Operating cash inflow of \$2.09m, a \$3.21m turnaround on PCP
- Cash receipts from customers of \$13.35m, up 62% vs PCP
- Borrowings reduced to \$1.50m from \$2.91m at 30 June 2025
- Basic EPS increased to 0.53 cents (1H25: 0.20 cents)

#### Business Highlights:

- Fastest growing probiotic brand in Australian community pharmacy, with 100% of the product range in growth
- #2 ranked brand across total vitamins at Terry White Chemmart and the fastest growing in the category
- First major above-the-line winter immunity campaign in development for H2
- Fullscript distribution partnership secured in Canada (announced January 2026)
- Ethics approval granted for first human clinical trial on proprietary BMB18 strain with La Trobe University
- Mecca and Go Vita distribution partnerships commenced in H1
- New CFO Lauren Dwyer commenced February 2026
- New 1,350 sqm warehouse facility secured in Brunswick, VIC, adding 500 pallet positions to support ongoing growth and international scale

For personal use only




Microbiome health company Biome Australia Limited (ASX: BIO) ('Biome' or 'the company') has released its Appendix 4D and Half Yearly Report for the half year ended 31 December 2025.

Biome is pleased to report record half-year sales revenue of \$12.40m, an increase of 40% vs PCP. H1 FY26 also delivered record EBITDA of \$1.47m (excluding share-based payments and including \$0.66m R&D tax incentive rebate; underlying EBITDA \$0.81m), the company's eighth consecutive quarter of positive EBITDA. Net profit after tax was \$1.18m for the half, up 172% on PCP. Gross margin of 61.1% was achieved. Basic earnings per share increased to 0.53 cents (1H25: 0.20 cents).

The company generated operating cash inflow of \$2.09m (1H25: outflow of \$1.12m), a \$3.21m turnaround on the prior corresponding period. Cash receipts from customers increased 62% to \$13.35m, outpacing revenue growth and reflecting improved collections and working capital management. Borrowings reduced to \$1.50m from \$2.91m at 30 June 2025. Cash at 31 December 2025 was \$3.36m. Q2 FY26 revenue of \$6.45m represents an annualised run rate of approximately \$25.8m exiting Q2.

### Quarterly Sales Revenue with Rolling 12 months sales



## Business Highlights

### Sales and Market Position

The Australian pharmacy channel continues to be the primary growth engine. Pharmacy scan data confirms Activated Probiotics is the #1 probiotic brand by revenue in community pharmacy and #2 overall when including Chemist Warehouse, and the highest growth brand in the category. Biome Daily is on track to become the #1 probiotic product in Australian pharmacy by units. Every product in the Activated Probiotics range grew through the half, with particularly strong performance from Biome Baby, Biome Dental, Biome Her and Biome Daily Kids.

At Terry White Chemmart, the company is now the #2 ranked brand across total vitamins and the fastest growing in the category. At Priceline, scan sales are growing at 48%+ MAT with significant opportunity to increase category ranking, highlighting further upside within the banner.

Pharmacy same store sales growth remained exceptionally strong through the half across all banners, reflecting deepening penetration within existing accounts and the benefit of practitioner endorsement supporting repeat purchase behaviour.

During the half, the company implemented new supplier programs with wholesale partners Symbion and API to enhance stock visibility and improve demand forecasting at store level. Biome is now live on Symbion's Engage platform and API's Power BI reporting tools, providing direct visibility into stock levels and demand forecasting at store level.

### Winter Immunity Campaign

Looking ahead to H2, Biome is launching its first major above-the-line advertising campaign, a national winter immunity campaign spanning outdoor, digital, and co-branded activity supported by key health retail partners. The campaign is designed to build consumer awareness of Activated Probiotics at scale, strategically timed to support the company's highest growth period of the year.

### International Expansion

International markets contributed meaningfully in H1, with the Canadian market continuing to build momentum following the Fullscript distribution partnership announced in January 2026. Combined with the existing Ecotrend relationship, Biome now has access to both the leading practitioner platform and a national wholesale network in Canada.

In Ireland, the partnership with Uniphar continues to develop since the July 2025 launch, providing wholesale distribution infrastructure and pharmacy access. In New

For personal use only



Zealand, the Propharma (EBOS Group) and Green Cross Health partnerships are establishing the same dual-channel model that has driven success in Australia.

### **New Distribution Channels**

In August 2025, Biome expanded into two new retail channels with Mecca and Go Vita, opening access to premium health and beauty and Australia's largest health food network respectively.

### **Product Innovation and R&D**

In May 2025, Biome launched Activated Therapeutics, a new practitioner-only brand with four specialised products targeting perimenopause symptoms (Oestro-ISO), gastrointestinal repair (Synbio-GOS), acid reflux (Pepti-BIOTIC), and weight management including GLP-1 medication support (Macro-PRO). The range was adopted by all key national pharmacy partners.

Ethics approval was granted for Biome's first human clinical trial on its proprietary probiotic strain, *Lactobacillus plantarum* BMB18, in partnership with La Trobe University. The randomised, double-blind, placebo-controlled trial commenced in February 2026 with 240 participants. BMB18 represents significant proprietary intellectual property for the company, having been registered with the internationally recognised DSMZ strain bank in Germany. The project is expected to underpin ongoing innovation and product development in future periods

### **Manufacturing and Supply**

Australian manufacturing options have been identified and are under evaluation. Supply continuity is maintained under the company's existing manufacturing arrangements while longer-term commercial terms are progressed.

### **Logistics and Infrastructure**

In December 2025, the company secured a new 1,350 sqm warehouse facility in Brunswick, VIC to support continued growth and international expansion. The facility adds approximately 500 pallet positions of capacity for both inbound and outbound logistics, and is now fully operational. The investment reflects the increasing volume demands of the business as it scales across multiple markets.

### **Team and Operations**

Key appointments during the half include Lauren Dwyer as CFO (commencing February 2026), a new Trade Marketing and Project Manager, and the establishment of a newly formed Education and Science department.

For personal use only



## Vision 27 Progress

The company remains on track and ahead of schedule on multiple strategic pillars of its Vision 27 plan, supported by an expanding distribution footprint, growing international revenue, proprietary IP development, and an extended product range. H1 FY26 marks the strongest half in the company's history and further accelerates progress toward the Vision 27 targets.

The company is well positioned for a strong H2. The cold and flu season historically drives the strongest sales quarter (Q4), and Biome enters it with a broader product range, deeper pharmacy penetration across all banners, and its first major above-the-line national advertising campaign. International markets are building scale simultaneously, with Fullscript now live in Canada, Unipharm developing in Ireland, and the dual-channel model established in New Zealand. The commencement of the BMB18 clinical trial adds a material proprietary IP dimension to the growth story. The company expects continued revenue growth and margin expansion in H2.

### **Biome Australia's Managing Director and Founder, Blair Vega Norfolk, commented:**

*"The first half of FY26 has been the strongest in the company's history, with record revenue, EBITDA, and net profit, and an eighth consecutive quarter of positive EBITDA. The operating leverage in our model is now clearly visible, with net profit growth of 172% significantly outpacing top-line growth."*

*In pharmacy, Activated Probiotics is the fastest growing probiotic brand in the category, and Biome Daily is closing in on the #1 position nationally. With our first major above-the-line advertising campaign launching into winter, we have the distribution reach and the momentum to continue building on these results.*

*Internationally, Canada is building momentum with Fullscript now live alongside Ecotrend, and our partnerships in Ireland and New Zealand continue to develop. The commencement of our BMB18 clinical trial with La Trobe University is a significant milestone for our proprietary IP strategy. I look forward to sharing further updates on what is shaping up to be another record year for Biome."*

–ENDS–

*This announcement has been authorised for release by the Board of Biome Australia Limited.*



## About Biome Australia Limited

Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines supported by clinical research. Biome aims to improve health outcomes and quality of life, making products accessible through professional health channels.

Incorporated in Australia in 2018, Biome distributes locally and internationally. In partnership with leading microbiome research organisations, Biome produces unique live biotherapeutic products with innovative delivery technologies improving stability and efficacy for its flagship Activated Probiotics® range.

Supported by randomised double-blind placebo-controlled clinical trials, Activated Probiotics® and Activated Therapeutics® help prevent and support management of various health concerns including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-recommended distribution, Biome educates health professionals on gut microbiota's systemic health effects, providing evidence-based natural medicines for prevalent chronic health concerns.

For more information visit: [www.biomeaustralia.com](http://www.biomeaustralia.com)

### Investor Relations

Lauren Dwyer - CFO

[corporate@biomeaustralia.com](mailto:corporate@biomeaustralia.com)

### Media enquiries

[media@activated.co](mailto:media@activated.co)

### Forward Looking Statements

This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of Biome (Forward Looking Statements). Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

The Forward Looking Statements are based on information available to Biome as at the date of this release. Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability


For personal use only



Biome Australia Limited  
192-194 Johnston Street  
Collingwood VIC 3066

+61 3 9017 5800  
[support@activated.co](mailto:support@activated.co)  
[biomeaustralia.com](http://biomeaustralia.com)

ASX:BIO  
ACN 627 364 014



or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.

For personal use only



**Biome Australia Limited**  
192-194 Johnston Street  
Collingwood VIC 3066

+61 3 9017 5800  
support@activated.co  
biomeaustralia.com

ASX: BIO  
ACN 627 364 014

